Implantica Publishes Annual Report 2025
Implantica AG has published its annual report for fiscal year 2025, highlighting the potential U.S. launch of its product RefluxStop®, pending FDA approval. The report outlines the company’s groundwork of clinical evidence and plans for global expansion in addressing GERD, a condition affecting over one billion people.
VADUZ, Liechtenstein, May 6, 2026 /PRNewswire/ — Implantica AG (publ), a med-tech company at the forefront of bringing advanced technology into the body, is publishing its annual report for the fiscal year 2025. The annual report is now available on the company’s website. “Implantica is…